Claims for Patent: 4,720,489

Summary for Patent: 4,720,489

Title:	Hair growth modification with ornithine decarboxylase inhibitors
Abstract:	The rate and character of human hair growth including androgen-stimulated beard hair growth in intact, sexually mature males is altered by the topical application out of a dermatologically acceptable carrier of a material capable of inhibiting the action of the enzyme ornithine decarboxylase. In a preferred practice of the invention, compositions containing such materials along with anti-androgen material are employed.
Inventor(s):	Shander; Douglas (Gaithersburg, MD)
Assignee:
Application Number:	06/661,019
Patent Claims:	1. The process of reducing the rate and altering the character of human hair growth which comprises the step of applying to the skin a composition containing an ornithine decarboxylase inhibitor. 2. The process as described in claim 1 in which said ornithine decarboxylase inhibitor is selected from the group including 2-(difluoromethyl)-2,5-diaminopentanoic acid; alpha-ethynyl ornithine; 6-heptyne-2,5-diamine; and 2-methyl-6-heptyne diamine. 3. The process as described in claim 2 resulting in the application of from about 1 to about 2000 micrograms of said ornithine decarboxylase inhibitor per square centimeter of skin. 4. The process as described in claim 2 resulting in the application of from about 50 to about 500 micrograms of said ornithine decarboxylase inhibitor per square centimeter of skin. 5. The process as described in claim 1 and in which said composition contains in addition an anti-androgen material selected from the group consisting of 5-alpha-reductase inhibitors and cytoplasmic androgen receptor-binding agents. 6. The process as described in claim 5 in which said anti-androgen is selected from the group consisting of progesterone; (5.alpha., 20-R)-4-diazo-21-hydroxy-20-methyl pregnan-3-one; (4R)-5-10-seco-19-Norpregna4,5-diene-3,10,20 trione; 4-androstene-3-one-17-carboxylic acid, and its methyl ester; 17-.beta.-N,N-diethylcarbamoyl-9-methyl4-aza-5.alpha.-androstane-3-one; 11-.alpha.-OH-progesterone; 17-.alpha.-OH-progesterone; and 20-.alpha.-OH-progesterone; cyproterone acetate; chlormadinone acetate; 17-alpha-propyltestosterone; 17-alpha-allyltestosterone; .alpha.-.alpha.-.alpha.-trifluoro-2-methyl-4'-nitro-m-propionotoluidide; 6.alpha.-bromo-17.beta.-hydroxy-17.alpha.-methyl-4-oxa-5.alpha.-androstane -3-one; 17.beta.-acetoxy-4.alpha.,5cyclo-A-homo-B-nor-5.alpha.-androst-1-ene-3one; and spironolactone. 7. The process as described in claim 6 in which about 1 to about 500 micrograms of said anti-androgen is applied per square centimeter of skin. 8. A topical composition for reducing the rate and altering the character of human hair growth comprising from about 0.01 to about 20% by weight of an ornithine decarboxylase inhibitor in combination with from about 0.01 to 10% by weight of an anti-androgen selected from the group consisting of 5-alpha-reductase inhibitors and cytoplasmic androgen receptor-binding agents. 9. A composition as described in claim 8 in which said ornithine decarboxylase inhibitor is selected from the group including 2-(difluoromethyl)-2,5-diaminopentanoic acid; alpha-ethynyl ornithine; 6-heptyne-2,5-diamine; and 2-methyl-6-heptyne diamine and said anti-androgen is selected from the group including progesterone; (5.alpha., 20-R)-4-diazo-21-hydroxy-20-methyl pregnan-3-one; (4R)-5-10-seco-19-Norpregna4,5-diene-3,10,20 trione; 4-androstene-3-one-17-carboxylic acid, and its methyl ester; 17-.beta.-N,N-diethylcarbamoyl-9-methyl4-aza-5.alpha.-androstane-3-one; 11-.alpha.-OH-progesterone; 17-.alpha.-OH-progesterone; and 20-.alpha.-OH-progesterone; cyproterone acetate; chlormadinone acetate; 17-alpha-propyltestosterone; 17-alpha-allyltestosterone; .alpha.-.alpha.-.alpha.-trifluoro-2-methyl-4'-nitro-m-propionotoluidide; 6.alpha.-bromo-17.beta.-hydroxy-17.alpha.-methyl-4-oxa-5.alpha.-androstane -3-one; 17.beta.-acetoxy-4.alpha.,5cyclo-A-homo-B-nor-5.alpha.-androst-1-ene-3one; and spironolactone.